Journal of Vaccine Research 2024, Vol.14, No.5, 217-230 http://medscipublisher.com/index.php/jvr 223 when immune responses to certain pathogens wane over time. Booster doses re-stimulate memory B and T cells, ensuring that the immune system remains primed to respond effectively to each of the included pathogens. Evidence from multi-pathogen vaccines like the combination vaccines for diphtheria, tetanus, and pertussis (DTP) has shown that booster doses significantly enhance long-term immunity by increasing antibody titers and maintaining immune memory (Malfertheiner et al., 2018). Similarly, booster doses of the COVID-19 vaccines have been shown to improve immune responses against both the original virus strain and emerging variants, ensuring ongoing protection in the face of evolving pathogens (Baden et al., 2020). Long-term protection provided by multi-pathogen vaccines is also enhanced by the use of adjuvants, which stimulate stronger and more durable immune responses. These adjuvants, when included in booster formulations, can further extend the duration of protection, making multi-pathogen vaccines an effective tool for managing diseases that require long-term immunity, such as respiratory infections and bacterial diseases. 6 Case Studies of Multi-Pathogen Vaccines 6.1 Case study 1: universal influenza vaccine Influenza viruses mutate frequently, making the development of a universal influenza vaccine a significant scientific challenge. Traditional flu vaccines need to be reformulated annually based on predictions of which strains will be dominant. A universal influenza vaccine, however, aims to provide broad protection against multiple strains of the virus, potentially reducing the need for yearly vaccination. Several universal influenza vaccines are currently under development, targeting conserved regions of the influenza virus that are less prone to mutation. One approach includes vaccines that induce cross-reactive immune responses by targeting the hemagglutinin stem, a part of the virus that remains relatively unchanged across different strains. Early-stage clinical trials have shown promising results, with vaccines inducing broad immunity against various influenza subtypes and demonstrating favorable safety profiles (Heath et al., 2021). The universal influenza vaccine represents a significant leap in multi-pathogen vaccine development, with the potential to drastically reduce the global burden of influenza and offer a model for similar efforts against other rapidly mutating viruses, such as coronaviruses. 6.2 Case study 2: vaccine for recurrent urinary tract infections Recurrent urinary tract infections (UTIs), often caused by Escherichia coli (E. coli), present a significant clinical challenge, particularly for individuals prone to frequent infections. The development of a multi-pathogen vaccine to prevent recurrent UTIs has focused on targeting the uropathogens responsible for these infections, primarily E. coli and other bacteria like Klebsiella pneumoniae. Recent advances in UTI vaccine development include subunit vaccines that use components of the bacterial pili, which are responsible for bacterial adhesion to the urinary tract. These vaccines aim to stimulate the production of antibodies that prevent bacteria from attaching to the bladder wall, thus preventing infection. Clinical trials of these vaccines have shown that they can reduce the incidence of recurrent infections in individuals with a history of frequent UTIs, with mild to moderate side effects reported (Sekuloski et al., 2018). The development of a multi-pathogen UTI vaccine could drastically reduce the use of antibiotics for recurrent infections, helping to combat antibiotic resistance while offering long-term protection against multiple uropathogens. 6.3 Case study 3: porcine reproductive and respiratory syndrome vaccine Porcine reproductive and respiratory syndrome (PRRS) is a significant viral disease affecting swine populations worldwide, causing reproductive failure in breeding animals and respiratory illness in young pigs. The economic impact of PRRS is substantial, prompting the need for effective vaccines that can control this multi-pathogen disease, which is caused by both European (PRRSV-1) and North American (PRRSV-2) viral strains.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==